Avantor, Inc. will outline its plans to transform the business by implementing a new operating model and advancing a multi-year cost optimization initiative. Under the new model, Avantor will transition from three geographic segments to two complementary business segments focused on customer needs: Laboratory Solutions and Bioscience Production. The Laboratory Solutions segment(LSS) represents an estimated $4.7 Billion in annual revenue and positions Avantor as a trusted partner at more than 300,000 customer locations in 180 countries.

The Laboratory Solutions segment leverages a comprehensive portfolio of products, services and digital solutions to enable insights in life science research, diagnostic and quality control workflows and creates a critical access point for seeding proprietary products to support Avantor's production segment. The Bioscience Production segment (BPS) represents an estimated $2.3 Billion in annual revenue and provides mission-critical, high-purity materials and solutions for bioprocessing, healthcare, and advanced technologies. Through this segment, Avantor is specified into 85% of the top 20 commercial biologic therapies and is the leading supplier of medical-grade silicones for a wide range of life-changing medical devices.